Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    STARTVerso
Show Display Options
Rank Status Study
1 Active, not recruiting Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Inmunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Condition: Hepatitis C, Chronic
Interventions: Drug: PegIFN/RBV;   Drug: BI201335;   Drug: BI201335 24W;   Drug: Bi 201335
2 Completed Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
Condition: Hepatitis C
Interventions: Drug: BI201335;   Drug: PegIFN/RBV
3 Completed Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)
Condition: Hepatitis C
Interventions: Drug: PegIFN/RBV;   Drug: BI 201335
4 Completed Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)
Condition: Hepatitis C, Chronic
Interventions: Drug: BI 201335;   Drug: Pegylated Interferon-alpha (IFN);   Drug: Ribavirin (RBV);   Drug: Placebo

Indicates status has not been verified in more than two years